|
Treatments characteristics |
|
| Parameter |
Value |
|
|
|
| No. of treatments |
106 |
| Total no. of examined KCALC/KDEL(ml min-1) |
179 (106 T0; 73 T18) |
| CVVHpost |
38 (19 T0; 19 T18) |
| CVVHpre |
30 (23 T0; 7 T18) |
| CVVHD |
29 (23 T0; 6 T18) |
| CVVHDF |
82 (42 T0; 42 T18) |
| Total prescribed KCALC (ml min-1) |
48.6 ± 24; 18–100 |
| CVVHpost |
35.6 ± 16; 16–66 |
| CVVHpre |
48.8 ± 19; 15–83 |
| CVVHD |
56.2 ± 28; 20–100 |
| CVVHDFa |
52.2 ± 24; 23–100 |
| Total prescribed net UF (ml h-1) |
250 ± 100; 0–500 |
| Treatment hours per day |
20 ± 3; 8.5–24 |
| Treatment hours per run |
17 ± 6; 5–24 |
| Downtime (hours) |
3 ± 2 |
|
aDuring continuous veno-venous hemodiafiltration (CVVHDF) modality, prescribed clearance was delivered with even hemofiltration and hemodialysis flow rates. Where errors are given, results are means ± SD; ranges follow a semicolon. CVVH, continuous veno-venous hemofiltration; CVVHD, continuous veno-venous hemodialysis; KCALC, calculator-estimated urea clearance; KDEL, delivered clearance evaluated from urea concentrations on simultaneous blood and effluent samples; T0, at therapy start; T18, after 18 to 24 hours of uninterrupted therapy. | |
Ricci et al. Critical Care 2005 9:R266 doi:10.1186/cc3517 |
|